Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer.

To evaluate the utility of contemporary health screening (HS) in the diagnosis of bladder cancer (BCa). We retrospectively reviewed 279,683 individuals who underwent HS between February 1995 and April 2015. Among these individuals, 74 were diagnosed with BCa within a year after the HS and were included in the analysis. Screen-detected BCa was defined as when a referral was made to a urologist due to microscopic hematuria (MH) on urinalysis, abnormal imaging, or any urological symptoms observed at the HS. Screen-undetected BCa was defined as when no referral was made to a urologist because of no abnormality observed at the HS, but a visit to a urological outpatient clinic later was followed by a BCa diagnosis. The incidences of screen-detected BCa and BCa in the Korean population were compared. Clinicopathological characteristics were compared between the screen-detected BCa and screen-undetected BCa groups. The detection rate of BCa was 17.2 per 100,000, which exceeded the 2020 estimated national crude incidence rate of 9.3 per 100,000 by approximately 1.7 times. Among the 74 patients diagnosed with BCa within a year after HS, 48 (64.9%) had screen-detected BCa. The screen-detected BCa group had a higher T stage (p = 0.009) and grade (p = 0.019) than the screen-undetected BCa group. However, the overall survival was not significantly different between the two groups (p = 0.677). A positive correlation between the MH grade and the T stage was identified (p = 0.001). Although HS is not focused on BCa screening, contemporary HS can contribute to the detection of BCa.

Citation

Chung-Un Lee, Wan Song, Michael Jakun Koo, Youngjun Boo, Jae-Hoon Chung, Minyong Kang, Hyun-Hwan Sung, Hwang-Gyun Jeon, Byong-Chang Jeong, Seong-Il Seo, Hyun-Moo Lee, Jeongyun Jeong, SeongSoo Jeon. Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer. Diagnostics (Basel, Switzerland). 2022 Apr 21;12(5)

PMID: 35626196

search → result